Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
Findlow H, Sow S, Borrow R, Tapia M, Haidara FC, Akinsola AK, Idoko OT, Diallo F, Adegbola R, Tang Y, Parulekar V, Chadha H, Mabey L, Holme D, Townsend K, Chaumont J, Laforce FM, Kulkarni PS, Marchetti E, Viviani S, Hassan-King M, Preziosi MP. Findlow H, et al. Among authors: parulekar v. Clin Vaccine Immunol. 2011 Sep;18(9):1492-6. doi: 10.1128/CVI.05020-11. Epub 2011 Jul 13. Clin Vaccine Immunol. 2011. PMID: 21752951 Free PMC article. Clinical Trial.
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
Tapia MD, Findlow H, Idoko OT, Preziosi MP, Kulkarni PS, Enwere GC, Elie C, Parulekar V, Sow SO, Haidara FC, Diallo F, Doumbia M, Akinsola AK, Adegbola RA, Kampmann B, Chaumont J, Martellet L, Marchetti E, Viviani S, Tang Y, Plikaytis BD, LaForce FM, Carlone G, Borrow R. Tapia MD, et al. Among authors: parulekar v. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S514-20. doi: 10.1093/cid/civ672. Clin Infect Dis. 2015. PMID: 26553683 Free PMC article. Clinical Trial.
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.
Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Préziosi MP, Elie C, Findlow H, Carlone G, Borrow R, Parulekar V, Plikaytis B, Kulkarni P, Imbault N, LaForce FM. Kshirsagar N, et al. Among authors: parulekar v. Vaccine. 2007 Sep 3;25 Suppl 1:A101-7. doi: 10.1016/j.vaccine.2007.04.050. Epub 2007 May 8. Vaccine. 2007. PMID: 17532101 Clinical Trial.
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Adegbola RA, Diop D, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, LaForce FM, Preziosi MP. Sow SO, et al. Among authors: parulekar v. N Engl J Med. 2011 Jun 16;364(24):2293-304. doi: 10.1056/NEJMoa1003812. N Engl J Med. 2011. PMID: 21675889 Free article. Clinical Trial.
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
Hirve S, Bavdekar A, Pandit A, Juvekar S, Patil M, Preziosi MP, Tang Y, Marchetti E, Martellet L, Findlow H, Elie C, Parulekar V, Plikaytis B, Borrow R, Carlone G, Kulkarni PS, Goel A, Suresh K, Beri S, Kapre S, Jadhav S, Preaud JM, Viviani S, LaForce FM. Hirve S, et al. Among authors: parulekar v. Vaccine. 2012 Oct 5;30(45):6456-60. doi: 10.1016/j.vaccine.2012.08.004. Epub 2012 Aug 13. Vaccine. 2012. PMID: 22898557 Clinical Trial.
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
Tapia MD, Sow SO, Haidara FC, Diallo F, Doumbia M, Enwere GC, Paranjape G, Hervé J, Bouma E, Parulekar V, Martellet L, Chaumont J, Plikaytis BD, Tang Y, Kulkarni PS, Hartmann K, Preziosi MP. Tapia MD, et al. Among authors: parulekar v. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S507-13. doi: 10.1093/cid/civ626. Clin Infect Dis. 2015. PMID: 26553682 Free PMC article. Clinical Trial.
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Diallo A, Sow SO, Idoko OT, Hirve S, Findlow H, Preziosi MP, Elie C, Kulkarni PS, Parulekar V, Diarra B, Cheick Haidara F, Diallo F, Tapia M, Akinsola AK, Adegbola RA, Bavdekar A, Juvekar S, Chaumont J, Martellet L, Marchetti E, LaForce MF, Plikaytis BD, Enwere GC, Tang Y, Borrow R, Carlone G, Viviani S. Diallo A, et al. Among authors: parulekar v. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S521-30. doi: 10.1093/cid/civ518. Clin Infect Dis. 2015. PMID: 26553684 Free PMC article. Clinical Trial.
Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants.
Kawade A, Babji S, Kamath V, Raut A, Kumar CM, Kundu R, Venkatramanan P, Lalwani SK, Bavdekar A, Juvekar S, Dayma G, Patil R, Kulkarni M, Hegde A, Nayak D, Garg BS, Gupta S, Jategaonkar S, Bedi N, Maliye C, Ganguly N, Uttam KG, Niyogi P, Palkar S, Hanumante N, Goyal N, Arya A, Aslam M, Parulekar V, Dharmadhikari A, Gaikwad D, Zade J, Desai S, Kang G, Kulkarni PS. Kawade A, et al. Among authors: parulekar v. Vaccine. 2019 May 1;37(19):2554-2560. doi: 10.1016/j.vaccine.2019.03.067. Epub 2019 Apr 4. Vaccine. 2019. PMID: 30955982 Clinical Trial.
A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.
Kulkarni PS, Desai S, Tewari T, Kawade A, Goyal N, Garg BS, Kumar D, Kanungo S, Kamat V, Kang G, Bavdekar A, Babji S, Juvekar S, Manna B, Dutta S, Angurana R, Dewan D, Dharmadhikari A, Zade JK, Dhere RM, Fix A, Power M, Uprety V, Parulekar V, Cho I, Chandola TR, Kedia VK, Raut A, Flores J; SII BRV-PV author group. Kulkarni PS, et al. Among authors: parulekar v. Vaccine. 2017 Oct 27;35(45):6228-6237. doi: 10.1016/j.vaccine.2017.09.014. Epub 2017 Sep 26. Vaccine. 2017. PMID: 28967523 Free PMC article. Clinical Trial.
Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.
Gogtay NJ, Munshi R, Ashwath Narayana DH, Mahendra BJ, Kshirsagar V, Gunale B, Moore S, Cheslock P, Thaker S, Deshpande S, Karande S, Kumbhar D, Ravish HS, Harish BR, Pisal SS, Dhere R, Parulekar V, Blackwelder WC, Molrine DC, Kulkarni PS. Gogtay NJ, et al. Among authors: parulekar v. Clin Infect Dis. 2018 Jan 18;66(3):387-395. doi: 10.1093/cid/cix791. Clin Infect Dis. 2018. PMID: 29020321 Clinical Trial.
22 results